{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T13:22:36Z","timestamp":1791638556758,"version":"4.3.4"},"reference-count":34,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,12,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Over the last decade, the advent of Bruton tyrosine kinase inhibitors (BTKi) has profoundly modified the therapeutic strategy in chronic lymphocytic leukemia (CLL), introducing the concept of treatment until progression. Initially, the bcl-2 inhibitor venetoclax (VEN) was used as a single agent and then was rapidly combined in VEN-based regimens associated with either anti-CD20 or with BTKi. These regimens yielded a high rate of complete remission, leading to their use as a fixed duration treatment. The decision between continuous treatment with BTKi and VEN-based combinations relies mostly on comorbidities, comedications, and patient\/physician preferences. Notably, with BTKi, cardiovascular comorbidities, hypertension, and potential pharmacological interactions should be carefully evaluated. On the other hand, the risk of tumor lysis syndrome with VEN should be monitored at treatment initiation. TP53 alteration and IGHV mutational status should also be assessed, as they remain important for therapeutic decisions. Fit patients with a TP53 wild type and IGHV-mutated CLL may still benefit from fludarabine-cyclophosphamide-rituximab chemoimmunotherapy (CIT), as it may result in a very long remission duration. VEN-based treatments are well tolerated, and no additional toxicity has been observed when combined with anti-CD20 or BTKi. The 1-year fixed-duration association of VEN plus obinutuzumab was evaluated in frontline for older adult patients. Nonetheless, considering the favorable outcome, an extension of indication for fit younger patients is expected. The association of VEN and BTKi is promising, even if the follow-up is still short. It is currently being tested against CIT, BTKi continuous treatment, and VEN plus anti-CD20.<\/jats:p>","DOI":"10.1182\/hematology.2021000233","type":"journal-article","created":{"date-parts":[[2021,12,10]],"date-time":"2021-12-10T12:19:21Z","timestamp":1639138761000},"page":"59-67","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":11,"title":["Frontline treatment in CLL: the case for time-limited treatment"],"prefix":"10.1182","volume":"2021","author":[{"given":"Vincent","family":"L\u00e9vy","sequence":"first","affiliation":[{"name":"D\u00e9partement de Recherche Clinique, H\u00f4pital Avicenne AP-HP, Universit\u00e9 Sorbonne Paris Nord, Bobigny, France, and INSERM CRESS-UMR 1153, H\u00f4pital Saint Louis, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Delmer","sequence":"additional","affiliation":[{"name":"Hematology Department, Reims University Hospital and Reims Champagne Ardenne University, Reims, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Cymbalista","sequence":"additional","affiliation":[{"name":"Hematology Biology, H\u00f4pital Avicenne, AP-HP, Universit\u00e9 Sorbonne Paris Nord, Bobigny, France, and INSERM UMR 978, Bobigny, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2021,12,10]]},"reference":[{"issue":"26","key":"2021121012084612300_hem2021000233C1","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1812836","article-title":"Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL","volume":"379","author":"Woyach","year":"2018","journal-title":"N Engl J Med"},{"issue":"3","key":"2021121012084612300_hem2021000233C2","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/s41375-019-0602-x","article-title":"Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL\/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study","volume":"34","author":"Burger","year":"2020","journal-title":"Leukemia"},{"issue":"9","key":"2021121012084612300_hem2021000233C3","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1016\/S1470-2045(20)30443-5","article-title":"Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial","volume":"21","author":"Al-Sawaf","year":"2020","journal-title":"Lancet Oncol"},{"issue":"25","key":"2021121012084612300_hem2021000233C4","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","article-title":"iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL","volume":"131","author":"Hallek","year":"2018","journal-title":"Blood"},{"issue":"1","key":"2021121012084612300_hem2021000233C5","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.annonc.2020.09.019","article-title":"Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Eichhorst","year":"2021","journal-title":"Ann Oncol"},{"issue":"5","key":"2021121012084612300_hem2021000233C6","doi-asserted-by":"crossref","first-page":"e473","DOI":"10.1097\/HS9.0000000000000473","article-title":"Diagnosis and treatment of chronic lymphocytic leukemia: recommendations of the French CLL Study Group (FILO)","volume":"4","author":"Quinquenel","year":"2020","journal-title":"Hemasphere"},{"issue":"5","key":"2021121012084612300_hem2021000233C7","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1111\/bjh.15080","article-title":"Optimising outcomes for patients with chronic lymphocytic leukaemia on ibrutinib therapy: European recommendations for clinical practice","volume":"180","author":"Gribben","year":"2018","journal-title":"Br J Haematol"},{"issue":"6","key":"2021121012084612300_hem2021000233C8","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1111\/bjh.16345","article-title":"Practical management of tumour lysis syndrome in venetoclax-treated patients with chronic lymphocytic leukaemia","volume":"188","author":"Gribben","year":"2020","journal-title":"Br J Haematol"},{"issue":"3","key":"2021121012084612300_hem2021000233C9","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1038\/s41375-020-0884-z","article-title":"Response to the conjugate pneumococcal vaccine (PCV13) in patients with chronic lymphocytic leukemia (CLL)","volume":"35","author":"Mauro","year":"2021","journal-title":"Leukemia"},{"issue":"23","key":"2021121012084612300_hem2021000233C10","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1182\/blood.2021011568","article-title":"Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia","volume":"137","author":"Herishanu","year":"2021","journal-title":"Blood"},{"issue":"2","key":"2021121012084612300_hem2021000233C11","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1182\/blood-2015-06-651125","article-title":"Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial","volume":"127","author":"Fischer","year":"2016","journal-title":"Blood"},{"issue":"1","key":"2021121012084612300_hem2021000233C12","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1470-2045(18)30788-5","article-title":"Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial","volume":"20","author":"Moreno","year":"2019","journal-title":"Lancet Oncol"},{"issue":"29","key":"2021121012084612300_hem2021000233C13","doi-asserted-by":"crossref","first-page":"4473","DOI":"10.1200\/JCO.2009.27.8762","article-title":"TP53 mutation and survival in chronic lymphocytic leukemia","volume":"28","author":"Zenz","year":"2010","journal-title":"J Clin Oncol"},{"issue":"12","key":"2021121012084612300_hem2021000233C14","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.3324\/haematol.2018.187583","article-title":"TP53 aberrations in chronic lymphocytic leukemia: an overview of the clinical implications of improved diagnostics","volume":"103","author":"Campo","year":"2018","journal-title":"Haematologica"},{"issue":"7","key":"2021121012084612300_hem2021000233C15","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/S1470-2045(16)30051-1","article-title":"First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial","volume":"17","author":"Eichhorst","year":"2016","journal-title":"Lancet Oncol"},{"issue":"12","key":"2021121012084612300_hem2021000233C16","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1056\/NEJMoa1313984","article-title":"Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions","volume":"370","author":"Goede","year":"2014","journal-title":"N Engl J Med"},{"issue":"5","key":"2021121012084612300_hem2021000233C17","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1056\/NEJMoa1817073","article-title":"Ibrutinib-rituximab or chemoimmunotherapy for chronic lymphocytic leukemia","volume":"381","author":"Shanafelt","year":"2019","journal-title":"N Engl J Med"},{"issue":"7574","key":"2021121012084612300_hem2021000233C18","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/nature15395","article-title":"Mutations driving CLL and their evolution in progression and relapse","volume":"526","author":"Landau","year":"2015","journal-title":"Nature"},{"issue":"2","key":"2021121012084612300_hem2021000233C19","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1038\/leu.2017.177","article-title":"Whole-genome sequencing of chronic lymphocytic leukaemia reveals distinct differences in the mutational landscape between IgHVmut and IgHVunmut subgroups","volume":"32","author":"Burns","year":"2018","journal-title":"Leukemia"},{"issue":"11","key":"2021121012084612300_hem2021000233C20","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1182\/blood-2018-09-873083","article-title":"Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations, and clinical impact","volume":"133","author":"Baliakas","year":"2019","journal-title":"Blood"},{"issue":"9","key":"2021121012084612300_hem2021000233C21","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1200\/JCO.2016.71.0822","article-title":"Clinical implications of novel genomic discoveries in chronic lymphocytic leukemia","volume":"35","author":"Lazarian","year":"2017","journal-title":"J Clin Oncol"},{"issue":"7762","key":"2021121012084612300_hem2021000233C22","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/s41586-019-1252-x","article-title":"Growth dynamics in naturally progressing chronic lymphocytic leukaemia","volume":"570","author":"Gruber","year":"2019","journal-title":"Nature"},{"key":"2021121012084612300_hem2021000233C23","article-title":"Fixed-duration ibrutinib and venetoclax (I\u200a+\u200aV) versus chlorambucil plus obinutuzumab (CLB+O) for first line (1L) chronic lymphocytic leukemia (CLL): primary analysis of the phase 3 GLOW study","author":"Arnon Kater","year":"2021","journal-title":"EHA Library"},{"issue":"9","key":"2021121012084612300_hem2021000233C24","doi-asserted-by":"crossref","first-page":"e470","DOI":"10.1016\/S2352-3026(19)30113-9","article-title":"Obinutuzumab and ibrutinib induction therapy followed by a minimal residual disease-driven strategy in patients with chronic lymphocytic leukaemia (ICLL07 FILO): a single-arm, multicentre, phase 2 trial","volume":"6","author":"Michallet","year":"2019","journal-title":"Lancet Haematol"},{"issue":"8","key":"2021121012084612300_hem2021000233C25","doi-asserted-by":"crossref","first-page":"e419","DOI":"10.1016\/S2352-3026(19)30104-8","article-title":"Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trial","volume":"6","author":"Davids","year":"2019","journal-title":"Lancet Haematol"},{"key":"2021121012084612300_hem2021000233C26","article-title":"Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations","volume-title":"Leukemia","author":"Jain","year":"2021"},{"issue":"22","key":"2021121012084612300_hem2021000233C27","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1056\/NEJMoa1900574","article-title":"Ibrutinib and venetoclax for first-line treatment of CLL","volume":"380","author":"Jain","year":"2019","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"2021121012084612300_hem2021000233C28","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1182\/blood-2020-134446","article-title":"Ibrutinib (Ibr) plus venetoclax (Ven) for first-line treatment of chronic lymphocytic leukemia (CLL)\/small lymphocytic lymphoma (SLL): 1-year disease-free survival (DFS) results from the MRD cohort of the phase 2 CAPTIVATE study","volume":"136","author":"Wierda","year":"2020","journal-title":"Blood"},{"issue":"3","key":"2021121012084612300_hem2021000233C29","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1182\/blood-2015-09-667675","article-title":"Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia","volume":"127","author":"Thompson","year":"2016","journal-title":"Blood"},{"issue":"suppl 1","key":"2021121012084612300_hem2021000233C30","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1182\/blood-2020-136977","article-title":"Clonal dynamics after venetoclax-obinutuzumab therapy: novel insights from the randomized, phase 3 CLL14 trial","volume":"136","author":"Al-Sawaf","year":"2020","journal-title":"Blood"},{"issue":"31","key":"2021121012084612300_hem2021000233C31","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1200\/JCO.2016.67.1305","article-title":"Minimal residual disease assessment improves prediction of outcome in patients with chronic lymphocytic leukemia (CLL) who achieve partial response: comprehensive analysis of two phase III studies of the German CLL study group","volume":"34","author":"Kovacs","year":"2016","journal-title":"J Clin Oncol"},{"key":"2021121012084612300_hem2021000233C32","unstructured":"European Medicines Agency Committee for Medicinal Products for Human Use. Appendix 4 to the guideline on the evaluation of anticancer medicinal products in man [updated 15 February 2016]. Accessed 10January2018. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2016\/02\/WC500201945.pdf."},{"issue":"6","key":"2021121012084612300_hem2021000233C33","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1038\/s41375-020-01009-z","article-title":"Prognostic value of high-sensitivity measurable residual disease assessment after front-line chemoimmunotherapy in chronic lymphocytic leukemia","volume":"35","author":"Letestu","year":"2021","journal-title":"Leukemia"},{"issue":"5","key":"2021121012084612300_hem2021000233C34","doi-asserted-by":"crossref","first-page":"e287","DOI":"10.1097\/HS9.0000000000000287","article-title":"Minimal residual disease assessment in CLL: ready for use in clinical routine?","volume":"3","author":"F\u00fcrstenau","year":"2019","journal-title":"Hemasphere"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2021\/1\/59\/1851402\/59levy.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2021\/1\/59\/1851402\/59levy.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,10]],"date-time":"2021-12-10T12:19:46Z","timestamp":1639138786000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2021\/1\/59\/483018\/Frontline-treatment-in-CLL-the-case-for-time"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,10]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12,10]]},"published-print":{"date-parts":[[2021,12,10]]}},"URL":"https:\/\/doi.org\/10.1182\/hematology.2021000233","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,12,10]]},"published":{"date-parts":[[2021,12,10]]}}}